WILMINGTON, DE — AstraZeneca began trading its ordinary shares on the New York Stock Exchange on Monday, February 2, 2026, marking a significant milestone as the global biopharmaceutical giant expands direct access to U.S. investors.
The move aligns trading of AstraZeneca’s ordinary shares across the NYSE, the London Stock Exchange, and Nasdaq Stockholm under a harmonized listing structure. The shares trade under the ticker symbol “AZN” on all three exchanges.
Company leaders described the shift as a strategic step designed to broaden investor participation and strengthen access to the world’s largest capital market.
“Today marks the start of an exciting new period for AstraZeneca, one which we believe gives broader access to the largest capital market in the world,” said Michel Demaré, chair of AstraZeneca. “This will allow even more investors to participate in AstraZeneca’s future. Our harmonized listing across New York, London and Stockholm reflects strong shareholder support for our growth strategy and positions AstraZeneca to deliver more innovative medicines to more patients around the world.”
Lynn Martin, president of NYSE Group, said the listing positions AstraZeneca to expand its global investor base while accelerating innovation in the biopharmaceutical sector.
AstraZeneca said its recent growth has been fueled by a diversified global portfolio and a series of new pipeline readouts representing a peak revenue opportunity of more than $10 billion. The company reiterated confidence in its long-term goal of reaching $80 billion in annual revenue by 2030 and launching 20 new medicines by that year.
Beyond 2030, the company said it is investing in transformative technologies intended to reshape medical treatment across its portfolio.
The company’s existing listings on the London Stock Exchange and Nasdaq Stockholm remain unchanged, and its shares will continue to be included in the FTSE 100 and OMX Stockholm 30 indices.
AstraZeneca’s American Depositary Shares and certain U.S. dollar-denominated bonds previously listed on Nasdaq ceased trading on January 30, 2026. Trading of AstraZeneca U.S. bonds on the NYSE began immediately following the launch of its ordinary shares on the exchange.
The debut on Wall Street signals a new chapter for the pharmaceutical heavyweight as it seeks to deepen its presence in U.S. capital markets while pursuing ambitious global growth targets.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.